Systimmune

Systimmune is a biotechnology company focused on developing innovative cancer immunotherapies. They specialize in creating multi-specific antibodies designed to target and eliminate cancer cells more effectively than traditional treatments. The company generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary therapies. Founded in 2014, Systimmune has made significant strides in the biotech industry, including advancing several candidates into clinical trials, which underscores its commitment to combating cancer through cutting-edge science.

Recent Posts by Systimmune

1-20 of 71